Health and Human Services awarded
$1.63Mcommitted so far
Stockpile storage and rotation eo 14398
The Department of Health and Human Services has already agreed to pay Merck $1.63M. The job runs until Sep 15, 2031.
Loading…
Vaccines and medicines (Keytruda, Gardasil).
In the last 90 days, no insider of Merck reported an open-market purchase and 17 open-market sales worth about $30M. Members of Congress disclosed 3 trades in its stock. US government contracts obligated about $2.24M to the company in the last 12 months. The latest 13F reports cover the quarter ending Jun 30, 2026. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$139.54
Last 12 months
+56.5%
Market value
$344B
S&P 500 +15.8% over the same dates. Prices adjusted for splits and dividends.
Bets against the stock: 34.4M shares sold short (1.4% of shares outstanding), +13.7% vs the previous count, 4.2 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Merck: 1 fund opened or increased a position in the latest 13F filings and 1 member of Congress disclosed purchases. 2 of 3 kinds of disclosure lean the same way. This counts filings; it does not say why, or what happens next. How well this has worked
Revenue
$16.6B
+5.1% vs the same quarter a year earlier
Free cash flow, last 12 months
$16.1B
This quarter $4.48B, a year earlier $2.53B
Net debt
$47.1B
Debt $53.9B, cash $6.85B, at Jun 30, 2026
Net income, last 12 months
$3.17B
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 4, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
17 sales
$30M sold. Insiders sell for many reasons.
New federal contracts, 12 months
$2.24M
10 contracts, 72.5% from one agency
Revenue, fiscal 2025
$65B
+1.3% vs the year before
Net income, fiscal 2025
$18.3B
As reported in the annual filing
Shares outstanding
2.47B
As of Jul 31, 2026
In fiscal 2025 the company spent $5.08B buying back its own shares and $8.18B on dividends. Cash actually paid, from its cash-flow statement.
Stockpile storage and rotation eo 14398
The Department of Health and Human Services has already agreed to pay Merck $1.63M. The job runs until Sep 15, 2031.
Traded Aug 19, 2026 · largest single filing $15,001–$50,000
Aug 19, 2026$15,001–$50,000
DetailsOfficial recordAug 19, 2026$15,001–$50,000
DetailsOfficial recordFrom a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Stock since the trade +5.0% · S&P 500 +0.3% · to Oct 5
Merck's General Counsel sold $10.7M of Merck shares. Nobody planned it ahead of time.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
A securities lawsuit naming the company as a defendant was filed on Feb 12, 2025 in the U.S. District Court, D. New Jersey. A filing is an allegation, not a finding.
IN RE MERCK & CO., INC. SECURITIES LITIGATION, 2:25-cv-01208Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). Coverage of court records is not complete, and shareholder derivative suits are not included.
Short sale volume: 37.1% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 47.7%. FINRA daily files, to Oct 5, 2026.
Fails to deliver: 7,268 shares (about $1.09M) were not delivered on time for settlement on Sep 8, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Last 12 months, adjusted daily closes
Adjusted close went from $88.80 on Oct 6, 2025 to $139.54 on Oct 5, 2026 (+57.1%). Disclosed activity in the last 12 months: 0 insider purchases, 35 insider sales (1 under pre-arranged plans), 5 Congress purchases, 3 Congress sales, 1 fund report of opening or adding and 0 fund reports of trimming or selling out (13F, quarter-end snapshots).
18 approvals or clearances and 2 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
106 active phase 3 trials and 83 active phase 2 trials led by this company, mostly in non-small cell lung cancer, carcinoma, renal cell, bladder cancer. The ones with the nearest registered primary completion date still ahead:
32 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.